Abstract:Modeling clinically relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI). This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicology. In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and non-parenchymal cells in a defined architecture. Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histologic analysis that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin positive, smooth muscle actin negative quiescent stellates. Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 weeks in culture. To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by standard pre-clinical models, were compared to the structurally related non-toxic drug Levofloxacin. Trovafloxacin induced significant, dose-dependent toxicity at clinically relevant doses (≤ 4uM). Interestingly, Trovafloxacin toxicity was observed without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports. Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compounds with differential profile. Thus, the combination of patient-derived primary cells with bioprinting technology here for the first time demonstrates superior performance in terms of mimicking human drug response in a known target organ at the tissue level.

In Vitro Human Liver Model for Toxicity Assessment with Clinical and Preclinical Instrumentation

Development of novel tools for the in vitro investigation of drug-induced liver injury

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs

An in Vitro Model for Long-Term Hepatotoxicity Testing Utilizing Rat Hepatocytes Entrapped in Micro-Hollow Fiber Reactor

A microvascularized in vitro liver model for disease modeling and drug discovery

The three dimensional organoids-based high content imaging model for hepatotoxicity assessment

In vitro and in silico liver models: Current trends, challenges and opportunities

Advanced Liver-on-a-Chip Model for Evaluating Drug Metabolism and Hepatotoxicity

Recent advances in the development of in vitro liver models for hepatotoxicity testing

A 3D primary human cell-based in vitro model of non-alcoholic steatohepatitis for efficacy testing of clinical drug candidates

A Cell Lines Derived Microfluidic Liver Model for Investigation of Hepatotoxicity Induced by Drug-Drug Interaction

Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro

Comprehensive Evaluation of Organotypic and Microphysiological Liver Models for Prediction of Drug-Induced Liver Injury

Multicellular, fluid flow-inclusive hepatic in vitro models using NANOSTACKS™: a human-relevant model for drug response prediction

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Advantages of in vitro 3D liver model in study of liver toxicity

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations

Liver organoid as a 3D in vitro model for drug validation and toxicity assessment